A naturally occurring psychoactive alkaloid derived from the Iboga shrub being developed for addiction and neuro-regeneration.
Investment Insights
AI-generated insights about Ibogaine from various financial sources
Sunday, April 12, 2026
High-potency, high-reward biotech asset gaining bipartisan political support and institutional validation from Stanford, though currently a Schedule I substance with cardiac risks.
Wednesday, April 1, 2026
Clinical trials show an 85-98% success rate in clearing opioid addiction and significant neuro-regenerative capacity for PTSD and TBI.
Sunday, April 12, 2026
High-potency, high-reward biotech asset gaining bipartisan political support and institutional validation from Stanford, though currently a Schedule I substance with cardiac risks.
Wednesday, April 1, 2026
Clinical trials show an 85-98% success rate in clearing opioid addiction and significant neuro-regenerative capacity for PTSD and TBI.